AJMC - Data Collaborations Are Driving Improvements to the Use of Real-World Evidence | Friends of Cancer Research

You are here

AJMC - Data Collaborations Are Driving Improvements to the Use of Real-World Evidence

Author: 
Silas Inman

The number of expedited FDA approvals for cancer drugs that are based on surrogate end points is increasing, leading many to search for new ways to uncover efficacy and safety data to justify the costs associated with these treatments. With the growth of data innovations and collaborations, the answer might be found in real-world evidence (RWE), according to presentations at the 9th Annual Research Symposium held in conjunction with the AMCP Nexus 2019 meeting,

 

"We can't expect this to directly replicate clinical research, but it's really important to advance this methodology," said Jeff Allen, PhD, president and chief executive officer, Friends of Cancer Research (FOCR), a group that was instrumental in the development of the breakthrough therapy designation. "If we're going to get back to the idea of how we're going to expedite the development of treatments for patients who have no other therapeutic options, but also carry out the responsibility to continue to evaluate the effect of these therapies and benefits over time, this is a way to advance that need in a different way."

 

To read the full article, please continue here: https://www.ajmc.com/conferences/amcp-nexus-2019/data-collaborations-are...